Entegrion Welcomes Peter C. Johnson, MD as Executive Vice President and Chief Business Officer
Published: Jan 27, 2009
Prior to joining Entegrion, Dr. Johnson was the Founder, President and CEO of Scintellix, LLC, a highly successful biomedical technology and decision analysis consultancy in Raleigh, NC. In addition to practicing Plastic Surgery for ten years at the University of Pittsburgh, Dr. Johnson founded and was the first President of the Pittsburgh Tissue Engineering Initiative. He then co-founded and was the Chairman and CEO of TissueInformatics. After its sale to Paradigm Genetics (which became Icoria), he served as the Senior Vice President for Life Sciences, Chief Medical Officer and Chief Business Officer of the merged entity.
We are delighted to have someone of Peters caliber on our team and look forward to working together to move our exciting platform of products forward, said Stan Eskridge, President and CEO.
Dr. Johnson serves on multiple for profit and non-profit boards. He is the National Chair for the University of North Carolina Medical Foundations Medical Excellence Fund and is the Co-Editor in Chief of the three part journal, Tissue Engineering. He is an avid fly fisherman, cook, artist and author.
Dr. Johnson received a BS degree from the University of Notre Dame, his MD from SUNY Upstate Medical University, trained in General Surgery at Case Western Reserve University and in Plastic Surgery at the University of Pittsburgh. He took a postdoctoral fellowship in thrombosis biology at Harvard University.
Entegrion is a life sciences company that selectively integrates synergistic technologies with those in its patent portfolio for development of novel devices and drugs for hemorrhage control, resuscitation and associated tissue repair. The company is based in North Carolinas Research Triangle Park, and is the inventor of Stasilon the hemostatic medical textile technology cleared by the FDA for use by prescription and also by consumers from which multiple hemorrhage control products are being made.
Building upon technologies licensed from the University of North Carolina, Entegrions portfolio includes platelet-derived platform technologies that are being developed as topical gels and sprays for tissue repair, infusible hemostatic agents for the control of internal hemorrhage, and novel vehicles for delivery of drugs to targeted tumors and other sites of internal bleeding. Entegrion has also developed proprietary techniques for drying plasma and other blood components to provide for long shelf life with rapid rehydration for emergent and clinical use. For more information, visit www.entegrion.com.